Gray KM, Baker NL, McClure EA, et al. - In adolescents and young adults, researchers assessed the effectiveness and safety of varenicline tartrate for smoking cessation. In total, 157 participants were enrolled (mean [SD] age, 19.1 [1.5] years) in this 2-group randomized, placebo-controlled, double-blind intention-to-treat clinical trial. They randomized participants in a 1:1 ratio to a 12-week course of varenicline (n = 77) or placebo (n = 80). Weekly smoking cessation counseling was received by all participant. Once applied to adolescent cigarette smokers' weekly cessation therapy, varenicline was well tolerated compared with placebo, but did not improve end-of-treatment abstinence. Varenicline, however, can accelerate abstinence and yield improvements in the outcomes of abstinence after treatment.